Pasireotide

Pasireotide

Clinical data
Trade names	Signifor
License data	EU EMA: Signifor
Routes of administration	Subcutaneous
ATC code	H01CB05 (WHO)
Legal status
Legal status	℞ (Prescription only)
Identifiers
IUPAC name [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate
Synonyms	SOM230
CAS Number	396091-73-9
PubChem (CID)	9941444
IUPHAR/BPS	2018
DrugBank	DB06663
ChemSpider	8117062
UNII	98H1T17066
KEGG	D10147
ChEBI	CHEBI:72312
ECHA InfoCard	100.211.883
Chemical and physical data
Formula	C58H66N10O9
Molar mass	1047.21 g/mol[1]
3D model (Jmol)	Interactive image
SMILES C1[C@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
InChI InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1 Key:VMZMNAABQBOLAK-DBILLSOUSA-N
(what is this?)  (verify)

Pasireotide (SOM230, trade name Signifor^[2]) is an orphan drug approved in the United States^[3] and Europe^[4] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.^[5][6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Pasireotide was approved for Cushing's disease by the EMEA in October 2009^[7] and by the FDA in December 2012.^[8]

Pasireotide LAR was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMEA one month earlier.^[9]

References

1. Pasireotide | C58H66N10O9 - PubChem http://pubchem.ncbi.nlm.nih.gov/compound/Pasireotide
2. Signifor® (pasireotide) Official Website for healthcare professionals outside the US http://www.signifor.com/
3. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/200677lbl.pdf
4. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002052/WC500128056.pdf
5. "Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing's disease". Retrieved 2012-07-08.
6. Mancini, Tatiana; Porcelli, Teresa; Giustina, Andrea (2010). "Treatment of Cushing disease: overview and recent findings". Therapeutics and Clinical Risk Management. 6: 505–16. doi:10.2147/TCRM.S12952 (inactive 2015-02-01). PMC 2963160. PMID 21063461.
7. EMEA Approval for Pasireotide
8. "FDA Approves Pasireotide for Cushing's Disease".
9. Tucker, Miriam E. FDA Approves Pasireotide for Treating Acromegaly, Medscape, December 17, 2014, Retrieved 2015-08-21